Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon

Dickson Shey Nsagha¹*, Elroy Patrick Weledji², Nguedia Jules Clement Assob³, Longdoh Anna Njunda³, Elvis Asangbeng Tanue³, Odette Dzemo kibu³, Charlotte Wenze Ayima³ and Marcelin Ngowe Ngowe²

Abstract

Background: The advent of HAART has been associated with a profound reduction in morbidity and mortality from HIV/AIDS. However, side effects and toxicities associated with HAART may lead to an increased risk for cardiovascular diseases. The aim of this study was to determine the prevalence of dyslipidemia and determining factors of derangements in lipid profile associated with the use of HAART regimens in people living with HIV/AIDS in Fako Division of the South West Region of Cameroon.

Methods: This cross-sectional study was conducted between March and August 2014. Lipid profile was determined after overnight fast and dyslipidemia diagnosed according to the US National Cholesterol Education Program III criteria. Socio-demographic characteristics were also collected using a questionnaire. Data was analyzed using STATA; chi-square test, student’s t-test, ANOVA and logistic regressions were computed.

Results: Two hundred and nine participants were recruited including 157 (75.1 %) on HAART and 52 (24.9 %) HAART-naïve. Antiretrovirals were drugs containing two nucleoside backbones (zidovudine/ lamivudine/ tenofovir) with either a non-nucleoside (nevirapine/efavirenz) or a protease inhibitor (lopinavir). No patient was treated with statins. Their mean age was 43.4 (±11.0) years. The mean CD4+ T cell count was 425 (±281) cells/µl after mean duration of HIV infection of 54.8 (±43.9) months and mean duration on ART of 63.7 (±41.4) months. The prevalence of total cholesterol (≥200 mg/dL) was 51.0 % in patients on HAART and 9.6 % pre-HAART patients (p < 0.0001), whereas LDL-cholesterol ≥130 mg/dL occurred in 36.9 % and in 7.7 % respectively, (p = 0.0001). Receiving HAART (adjusted odds ratio =6.24, 95 % CI: 2.33–17.45, p < 0.0001) and HIV duration of 42 months and more (aOR = 2.26, 95 % CI: 1.16–4.42, p = 0.017) were independently associated with total cholesterol (≥200 mg/dL). Receiving HAART (aOR = 5.28, 95 % CI: 1.17–16.32, p = 0.004) was independently associated with raised LDL-cholesterol values. The adjusted odds ratio (95 % CI) of BMI ≥25.0 kg/m² versus BMI < 25.0 kg/m² was 3.25 (1.44–7.34) for triglycerides ≥150 mg/dL.

Conclusion: HAART regimens were significantly associated with atherogenic lipid profile. Lipid profile should be monitored in HIV/AIDS patients on therapy so that any negative effects of HAART are optimally managed.
Background
The introduction and widespread use of combination antiretroviral therapy (ART) referred to as highly active antiretroviral therapy (HAART) in the mid 1990s, has led HIV-infected individuals to experience a dramatic decline in immunodeficiency-related events, including causes of death [1]. The advent of HAART has been associated with a profound reduction in morbidity and mortality from HIV/AIDS [2]. However, antiretroviral drugs also have side effects of varying severity. Disorders of lipid metabolism associated with HAART have been largely described in the developed and developing countries, mainly in patients on treatment regimens including protease inhibitors (PIs) and stavudine [3]. Treatment regimens including nevirapine and efavirenz have also been reported to induce lipid derangements [4]. ART can induce raised levels of total cholesterol (TC), LDL-cholesterol (LDL-c) and triglycerides (TG), and variables effects on HDL-cholesterol (HDL-c) levels [3]. Also, several reports have documented increased prevalence of hypertriglyceridemia, and low HDL-c in both HAART-treated and HAART-naïve patients [5]. Side effects and toxicities are associated with these highly effective therapies and there is growing concern that the metabolic complications associated with HIV and antiretroviral therapy may lead to an increased risk for cardiovascular diseases [6]. These ART-induced lipid derangements are potentially atherogenic and can increase cardiovascular risk [7]. There is scarcity of information in support of lipid profile derangements associated with HAART use in sub-Saharan Africa [8]. The aim of the present study was to determine the prevalence of dyslipidemia and determining factors of derangements in lipid profile associated with the use of HAART regimens in people living with HIV/AIDS in Fako Division of the South West Region of Cameroon.

Methods
Study setting and participants
This was a hospital-based cross-sectional study. Participants were recruited between March and August 2014 at treatment centers of people living with HIV/AIDS (PLWHA) in the Limbe and Buea Regional Hospitals in Fako Division, South West Region of Cameroon. Two groups of participants were selected. Group one was made up of individuals living with HIV/AIDS who had been receiving HAART for at least 6 months and reported by the treatment centres as non-defaulters (ART group). The second group was made up of individuals newly diagnosed with HIV but who were not yet receiving HAART (ART-naïve group). All participants were 21 years of age and above. Participants receiving lipid altering therapies, pregnant women, known diabetes mellitus patients, those with renal failures and patients who refused to be part of the study were excluded.

Data collection and measurements
For all participants, structured questionnaires were used to collect data on the socio-demographic characteristics and patients’ record were reviewed for information on their current CD4+ T cell count, HIV and HAART status. Body mass index and blood pressure were also measured. About 5 ml of venous blood sample was collected from each participant through venipuncture after a 12 h overnight fast and centrifuged at 2500 cycles/min for 10 min, and serum was obtained for fasting blood sugar and lipid profiles measurements. Fasting blood sugar and lipid profile were assessed through enzymatic methods (INMESCO, GmbH (L-S 04/2009) for all participants including total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), low density lipoprotein-cholesterol (LDL-c) and triglycerides (TG). The TC/HDL-c ratio was also calculated. In accordance with the US National Cholesterol Education Program, Adult Treatment Panel III (NCEP-ATP III) guidelines, abnormal lipid profile was defined as TC ≥ 200 mg/dL, HDL-c < 40 mg/dL, LDL-c ≥ 130 mg/dL, TG ≥ 150 mg/dL and TC/HDL-c ratio ≥ 5 [9].

Ethical considerations
Ethical Clearance was obtained from the Institutional Review Board of the Faculty of Health Sciences of the University of Buea (Reference No 2014–02–0193). Administrative authorization was obtained from the Regional Delegation of the Ministry of Public Health and the District Health Services. The purpose of the study and the role of the participants were well explained in the consent form to the participants and participation could only take place after the participant had read and signed the informed consent form voluntarily.

Data analysis
Data entry and Database management was computed using Microsoft excel 2010 (Microsoft Corporation Inc, USA). Statistical analyses were done using STATA version 10.1. Chi-square test was used to evaluate differences in frequency distribution. Student’s t-test and analysis of variance (ANOVA) were used to assess differences between group means. A single model logistic regression was computed to determine the association of independent factors with abnormal level of each lipid profile. P-value less than 0.05 were considered as statistically significant at 95 % confidence level.

Results
Demographic characteristics of participants
A total number of 209 participants were enrolled in the study, with 51 (24.4 %) males and 158 (75.6 %) females. Two groups of patients were investigated: the first group of 157 HIV-infected patients [34 (21.7 %) males, 123 (78.3 %) females], were currently receiving HAART; the
second group of 52 HIV-infected patients [17 (32.7 %) males, 35 (67.3 %) females], were HAART inexperienced. The mean age of individuals who were on HAART was 44.9 (±10.7) years while that of pre-HAART was 38.8 (±10.8) years (Table 1). The distribution of first-line ART regimens were as follows: AZT/3TC/NVP (80 participants), AZT/3TC/EFV (2 participants), TDF/3TC/NVP (21 participants) and TDF/3TC/EFV (41 participants). The second-line ART regimen was TDF/3TC/LPVr with 13 participants. Among HAART patients, 82 (52.2 %) were on zidovudine (AZT), 75 (47.8 %) on tenofovir (TDF), 43 (27.4 %) on nevirapine (NVP), 43 (27.4 %) on efavirenz (EFV) and 13 (8.3 %) on lopinavir (LPVr). All regimens included 3TC. ART patients who had been on treatment for an average of 64 (±41) months were reported as non-defaulters within the past six months. The mean CD4+ T cell count in the two groups was 425 (±280) cells/μl after a mean duration of HIV infection of 54.8 (±43.9) months. HAART experienced patients had been on HAART for a mean duration of 63.7 (±41.4) months. Thirty eight (18.2 %) patients reported drinking alcohol but only four admitted they were current cigarette smokers. Obesity, hypertension and diabetes mellitus were screened in 48 (23.0 %), 46 (22.0 %) and 5 (2.4 %) of the participants respectively (Table 1).

**Dyslipidemia and characteristics of lipid profiles**

The mean TC and mean LDL-c were significantly higher in patients on HAART than in HAART-naïve patients (p < 0.001). The mean TG and TC/HDL-c were significantly higher in participants on HAART than their HAART inexperienced counterparts (p < 0.05). There was no statistically significant difference between the two groups for mean HDL-c (Table 2). The prevalence of TC ≥ 200 mg/dL and LDL-c ≥ 130 mg/dL were significantly higher in the HAART treated group when compared to the pre-HAART group. However, the prevalence of HDL-c below 40 mg/dL, TG > 150 mg/dL and TC/HDL-c ≥ 5 were not statistically significantly different in pre-HAART group when compared to those on HAART treatment (Table 2).

**Table 1** General characteristics of the study population by HAART status

| Variables                  | HAART experienced Group (n = 157) | HAART-naive Group (n = 52) | Total        | p-value |
|----------------------------|-----------------------------------|----------------------------|--------------|---------|
| Gender                     | Male, n(%)                        | 34 (21.7)                  | 17 (32.7)    | 51 (24.4) |
|                            | Female, n(%)                      | 123 (78.3)                 | 35 (67.3)    | 158 (75.6) |
| Age (years)                | Mean ± SD                         | 44.9 (10.7)                | 38.8 (10.8)  | 43.4 (11.0) | 0.0002 |
|                            | 21-30 years, n(%)                 | 12 (7.6)                   | 12 (23.1)    | 24 (11.5)  |
|                            | 31-40 years, n(%)                 | 48 (30.6)                  | 19 (36.5)    | 67 (32.1)  |
|                            | 41-50 years, n(%)                 | 52 (33.1)                  | 15 (28.8)    | 67 (32.1)  |
|                            | > 50 years, n(%)                  | 45 (28.7)                  | 6 (11.5)     | 51 (24.4)  |
| BMI (kg/m²)                | Mean ± SD                         | 27.0 (5.4)                 | 25.3 (4.6)   | 26.6 (5.3) | 0.0188 |
|                            | < 18 kg/m², n(%)                  | 3 (1.9)                    | 1 (1.9)      | 4 (1.9)    |
|                            | 18-24.9 kg/m², n(%)               | 64 (40.8)                  | 2548.1       | 89 (42.6)  |
|                            | 25.0-29.9 kg/m², n(%)             | 50 (31.8)                  | 18 (34.6)    | 68 (32.5)  |
|                            | ≥ 30 kg/m², n(%)                  | 40 (25.5)                  | 8 (15.4)     | 48 (23.0)  |
| CD4+ T cell count*         | Mean ± SD                         | 430.3 (301.2)              | 411 (222.5)  | 424.9 (280.6) | 0.7389 |
|                            | < 200 cells/μl                    | 20 (23.5)                  | 6 (18.2)     | 26 (22.0)  |
|                            | 200-499 cells/μl                  | 36 (42.4)                  | 14 (42.4)    | 50 (42.4)  |
|                            | ≥ 500 cells/μl                    | 29 (34.1)                  | 13 (39.4)    | 42 (35.6)  |
| Alcohol intake             | No, n(%)                          | 131 (83.4)                 | 40 (76.9)    | 171 (81.8) |
|                            | Yes, n(%)                         | 26 (16.6)                  | 12 (23.1)    | 38 (18.2)  |
| Cigarette smoking          | No, n(%)                          | 154 (98.1)                 | 51 (98.1)    | 205 (98.1) |
|                            | Yes, n(%)                         | 03 (1.9)                   | 01 (1.9)     | 04 (1.9)   |
| Hypertension               | Not present, n(%)                 | 118 (75.2)                 | 45 (86.5)    | 163 (78.0) |
|                            | Present, n(%)                     | 39 (24.8)                  | 07 (13.5)    | 46 (22.0)  |
| Diabetes Mellitus          | Not present, n(%)                 | 154 (98.1)                 | 50 (96.2)    | 204 (97.6) |
|                            | Present, n(%)                     | 03 (1.9)                   | 02 (3.8)     | 05 (2.4)   |
| Obesity                    | Not present, n(%)                 | 117 (74.5)                 | 44 (84.6)    | 161 (77.0) |
|                            | Present, n(%)                     | 40 (25.5)                  | 08 (15.2)    | 48 (23.0)  |

HAART-Highly Active Antiretroviral Therapy, CD-Cluster of differentiation, SD-Standard Deviation, *-CD4+ T cell count values available for n = 118
Total cholesterol and triglyceride levels differed among the HAART regimens

The mean TC was higher in patients on TDF than those on AZT among the nucleoside reverse transcriptase inhibitor (NRTIs) based treatment. Among the non-nucleoside reverse transcriptase inhibitor (NNRTIs) based treated patients, the mean TC was also higher in patients on EFV compared to NVP. Although this was not statistically significant, it was above the normal cut off point. The mean TG was statistically significantly higher in patients on TDF compared to AZT, and EFV compared to NVP (\(p = 0.009\) and 0.004 respectively) (Table 3). No significant difference was observed in the prevalence of lipid profile derangements between patients receiving AZT compared to those on TDF; and patients treated with EFV compared to those treated with NVP (Table 3). No significant difference was observed in the mean lipid derangements, and the percentages between protease inhibitors (PIs) treated and non-PIs treated patients. However, the mean TG value was slightly higher in PIs based patients (146.8 ± 59.3) compared to non-PIs based (114.5 ± 65.7) (\(p = 0.0604\)).

Dyslipidemia with CD4\(^+\) T cell count, hypertension, diabetes mellitus and obesity

No significant difference was observed in the mean lipid profile parameters in the different CD4\(^+\) T cell count categories. HAART experienced participants with CD4\(^+\) T cell counts < 200 cells/\(\mu\)l and ≥ 500 cells/\(\mu\)l had higher mean TC values (227.9 (±70.7) and 230.0 (±101.7) respectively. No significant difference was found between mean values of lipid derangements and presence or absence of hypertension and diabetes mellitus. However, hypertensive patients had higher mean values of raised TC (203.1 ± 80.6) compared to non-hypertensive (190.6 ± 68.3) (\(p = 0.2942\)). Obese patients had higher mean values of raised TC (218.4 ± 83.1) compared to the non-obese (185.9 ± 65.7) (\(p = 0.0052\)). Also, obese patients had higher mean values of LDL-c (128.5 ± 76.5) compared to the non-obese (97.7 ± 61.7) (\(p = 0.0045\)).

Association of gender, BMI, HIV duration and HAART use with abnormal lipid profiles

The female gender was significantly and positively associated with raised TC (OR: 2.03, 95 % CI: 1.03-4.98, \(p = 0.042\)). The BMI of 25 kg/m\(^2\) and higher was significantly associated with raised TG (OR: 0.30, 95 % CI: 0.12-0.75, \(p = 0.010\)). The duration of HIV infection of 42 months and higher was significantly associated with raised TC and increased TG (\(p = 0.045\) and 0.035 respectively). The odds ratio (95 % CI) of HIV infection duration of 42 months and higher versus less than 42 months was 0.51 (0.26-0.99) for TC ≥ 200 mg/dL and 0.36 (0.14-0.93) for TG ≥ 150 mg/dL. Being on HAART treatment for more than 55 months was significantly associated with raised TC and raised TG, with 95 % CI odds ratio of 0.47 (0.25-0.90) and 0.31 (0.13-0.74) respectively (Table 4).

Adjusting for potential confounding factors such as gender, age, BMI, duration with HIV and HAART initiation, receiving HAART was significantly and positively associated with raised TC (OR: 2.03, 95 % CI: 1.03-4.98, \(p = 0.042\)). The BMI of 25 kg/m\(^2\) and higher was significantly associated with raised TG (OR: 0.30, 95 % CI: 0.12-0.75, \(p = 0.010\)). The duration of HIV infection of 42 months and higher was significantly associated with raised TC and increased TG (\(p = 0.045\) and 0.035 respectively). The odds ratio (95 % CI) of HIV infection duration of 42 months and higher versus less than 42 months was 0.51 (0.26-0.99) for TC ≥ 200 mg/dL and 0.36 (0.14-0.93) for TG ≥ 150 mg/dL. Being on HAART treatment for more than 55 months was significantly associated with raised TC and raised TG, with 95 % CI odds ratio of 0.47 (0.25-0.90) and 0.31 (0.13-0.74) respectively (Table 4).

Table 2 Serum lipid profiles of study participants by HAART status

| Parameters                          | HAART experienced Group (n = 157) | HAART naïve Group (n = 52) | p-value   |
|-------------------------------------|----------------------------------|---------------------------|-----------|
| Total cholesterol, mean ± SD        | 208.7 (71.9)                     | 147.4 (44.6)              | < 0.0001  |
| ≥ 200 mg/dL                         | 80 (51.0 %)                      | 5 (9.6 %)                 | < 0.0001  |
| LDL-cholesterol, mean ± SD          | 117.6 (68.2)                     | 65.9 (42.0)               | < 0.0001  |
| ≥ 130 mg/dL                         | 58 (36.9 %)                      | 4 (7.7 %)                 | 0.0001    |
| HDL-cholesterol, mean ± SD          | 67.0 (62.6)                      | 62.5 (26.3)               | 0.6153    |
| < 40 mg/dL                          | 22 (14.0 %)                      | 7 (13.5 %)                | 0.9257    |
| Triglycerides, mean ± SD            | 117.2 (59.3)                     | 97.7 (57.5)               | 0.0396    |
| ≥ 150 mg/dL                         | 32 (20.4 %)                      | 9 (17.3 %)                | 0.6257    |
| TC/HDL-cholesterol ratio, mean ± SD | 3.7 (2.6)                        | 2.8 (1.7)                 | 0.0205    |
| ≥ 5                                 | 24 (15.3 %)                      | 3 (5.8 %)                 | 0.0769    |

HAART- Highly Active Antiretroviral Therapy, TC-Total Cholesterol, HDL-High-Density Lipoprotein, LDL-Low-Density Lipoprotein, SD-Standard Deviation
the ratio of TC/HDL-c but this was not significant (Table 5).

**Discussion**

The aim of this study conducted in a resource-poor setting was to determine the prevalence of dyslipidemia and determining factors of derangements in lipid profile associated with the use of HAART regimens in HIV/AIDS patients. We found that CD4+ T cell count in the HAART group was higher but not significantly different from the HAART-naïve group. Though not significantly different, this shows the effects of HAART in improving the immunological properties of the HIV treated participants. Our finding is contrary to that observed by D’Ascenzo and colleague [10] where CD4+ T cell count of < 200 cells/μL was associated with increased risk of myocardial infarction and cardiovascular instability. The reason for lack of association between lipid parameters in our cohort of HIV/AIDS patients and the immune status may be related to the close similarity in the CD4+ T cell count as most patients were in the CD4+ T cell count range 200–499 cells/μL and above. The study has demonstrated a high prevalence of lipid derangements (64.3 %) in HIV patients receiving HAART. Though high, the prevalence of dyslipidemia in our study is similar to the reported rate of 70.2 % in patients receiving ART in a rural Cameroonian population [11], but lower than that observed in an urban population of Southern Ethiopia with 82.3 % [12], and 76.0 % observed in HAART-naïve patients in Tanzania [13]. We found that the proportions of hypercholesterolemia and raised levels of LDL-c were significantly higher in the HAART group compared to the HAART-naïve group. The described raised lipid profiles (TC and LDL-c) are atherogenic [9, 14], and were still present even after adjusting for confounders and suggests a potential risk for the development of cardiovascular diseases in a significant proportion of HIV-infected patients in the near future. We found that the prevalence of raised TC in the HAART group was high. This prevalence is higher than that reported from two similar studies in Cameroon [11, 15], and that found in rural Ugandans [8], where participants were followed for 24 months for lipid derangements. More than 50 % of our HAART experienced participants were either overweight or obese and this might have a contributing factor on raised TC. Moreover, the

| Lipid profile | AZT based (n = 82) | TDF based (n = 75) | p-value |
|---------------|-------------------|-------------------|---------|
| Total cholesterol, mean ± SD | 205.2 (66.3) | 212.3 (77.8) | 0.540 |
| ≥ 200 mg/dL | 41 (50.0 %) | 39 (52.0 %) | 0.802 |
| LDL-cholesterol, mean ± SD | 115.9 (63.2) | 119.5 (73.6) | 0.744 |
| ≥ 130 mg/dL | 27 (32.9 %) | 31 (41.3 %) | 0.276 |
| HDL-cholesterol, mean ± SD | 70.1 (29.9) | 63.7 (25.6) | 0.153 |
| < 40 mg/dL | 13 (15.9 %) | 9 (12.0 %) | 0.482 |
| Triglycerides, mean ± SD | 102.4 (46.9) | 133.4 (67.1) | 0.009 |
| ≥ 150 mg/dL | 12 (14.6 %) | 20 (26.7 %) | 0.060 |
| TC/HDL-cholesterol ratio, mean ± SD | 3.6 (2.7) | 3.9 (2.4) | 0.405 |
| ≥ 5 | 12 (14.6 %) | 12 (16.0 %) | 0.808 |

**Table 3** Prevalence of abnormal lipid profiles among patients treated with NRTIs and NNRTIs based antiretroviral regimens

HAART: Highly Active Antiretroviral Therapy, TC-Total Cholesterol, HDL-High-Density Lipoprotein, LDL-Low-Density Lipoprotein, AZT-Zidovudine, TDF-Tenofovir, NVP-Nevirapine, EFV-Efavirenz, SD-Standard Deviation
mean TC was also significantly higher in the obese participants compared to the non-obese. However, there are suggestions that the magnitude of HAART induced lipid derangements could vary across populations and settings. The prevalence of high LDL-c in our study was lower than that reported in urban Cameroon (43.5 %) [15], but higher than that observed in rural Cameroon (33.3 %) [11], and similar to the prevalence reported from India [16]. However, the mean LDL-c was significantly higher in the obese participants compared to the non-obese. The prevalence of raised TG in our study was lower than that reported in an urban Cameroon study (46.4 %) [15], and in the rural Cameroon setting (51.8 %) [11], and India [16], but similar to that reported in Kenya [17]. We found comparable percentages of HAART experienced group (14.0 %) and pre-HAART (13.5 %) who had decreased HDL-c. The HDL-c level was unaffected by HAART status in our study which is not in accordance with the findings of Pujari and colleagues [18] in whose study an 18-month treatment with first-line ART regimens was associated with significant increase in HDL-c level.

Several studies have found that stavudine was more involved in the occurrence of lipid derangements as compared with other NRTIs [19–22]. However, instead of stavudine, our participants were either on tenofovir or zidovudine. We found no difference in lipid profiles (TC, LDL-c and HDL-c) when participants on tenofovir were compared to those on zidovudine. This is in line with the findings of Buchacz and colleagues in Uganda [8], and those of Yone and colleagues in Cameroon [15]. We observed significantly higher TG in patients on tenofovir compared to those on zidovudine. Most of the patients on tenofovir were also on lopinavir, a protease inhibitor that has been associated with adverse lipid profiles [23, 24]. In line with the reports from rural Uganda [8], Cameroon [15] and India [4], we found no significant difference in lipid profiles (TC, LDL-c and HDL-c) of patients on efavirenz compared to those on nevirapine. In the present study, the raised TC and LDL-c were significantly and positively associated with the use of HAART treatment, and the findings are in line with another study conducted in Cameroon [15]. Moreover, NNRTIs have been reported to derange lipid profiles during therapy [25]. However, supportive evidences are very scarce in Sub-Sahara African countries concerning lipid derangements in patients receiving NNRTIs treatment regimens [8, 26]. We found a similar scenario with other cross-sectional studies [11, 15, 27] carried out in resources-constrained settings with

### Table 4: Association of variables with abnormal lipid profile levels among HAART treated participants

| Explanatory variables | TC ≥ 200 mg/dL | LDL-c ≥ 130 mg/dL | HDL-c < 40 mg/dL | TG ≥ 150 mg/dL |
|-----------------------|---------------|------------------|-----------------|---------------|
| Gender (Female)       | 2.3 (1.03-4.98) | 1.29 (0.58-2.89) | 0.54 (0.20-1.44) | 0.52 (0.22-1.25) |
| p-value               | 0.042         | 0.532            | 0.217           | 0.144         |
| Age > 40 years        | 0.81 (0.43-1.56) | 1.18 (0.61-2.31) | 0.93 (0.36-2.37) | 0.70 (0.30-1.60) |
| p-value               | 0.535         | 0.621            | 0.879           | 0.391         |
| BMI ≥ 25 kg/m2        | 0.80 (0.42-1.51) | 0.82 (0.43-1.59) | 0.92 (0.37-2.30) | 0.30 (0.12-0.75) |
| p-value               | 0.490         | 0.558            | 0.857           | 0.010         |
| CD4+ T cell count < 200 cells/μl | 0.80 (0.29-2.17) | 0.72 (0.26-1.97) | 0.58 (0.13-2.55) | 0.64 (0.17-2.36) |
| p-value               | 0.652         | 0.518            | 0.468           | 0.506         |
| HIV duration ≥ 42 months | 0.51 (0.26-0.99) | 0.59 (0.29-1.18) | 0.66 (0.24-1.79) | 0.36 (0.14-0.93) |
| p-value               | 0.045         | 0.136            | 0.413           | 0.035         |
| HAART duration > 55 months | 0.47 (0.25-0.90) | 0.58 (0.30-1.11) | 0.77 (0.31-1.92) | 0.31 (0.13-0.74) |
| p-value               | 0.022         | 0.101            | 0.572           | 0.008         |
| Hypertension          | 1.02 (0.49-2.10) | 0.94 (0.44-2.00) | 0.87 (0.30-2.54) | 0.81 (0.32-2.06) |
| p-value               | 0.962         | 0.876            | 0.805           | 0.664         |
| Diabetes Mellitus     | 0.47 (0.04-5.34) | 0.85 (0.08-9.59) | NA              | 8.27 (0.73-94.2) |
| p-value               | 0.546         | 0.896            | NA              | 0.089         |
| Obesity               | 1.88 (0.90-3.92) | 2.08 (1.00-4.32) | 1.11 (0.40-3.08) | 1.44 (0.61-3.38) |
| p-value               | 0.093         | 0.050            | 0.835           | 0.403         |
| Alcohol intake        | 1.38 (0.59-3.24) | 0.72 (0.29-1.78) | 1.14 (0.35-3.70) | 2.49 (0.99-6.27) |
| p-value               | 0.453         | 0.476            | 0.825           | 0.054         |

TC-Total Cholesterol, LDL-c-Low-Density Lipoprotein Cholesterol, HDL-c-High-Density Lipoprotein Cholesterol, TG-Triglyceride, HAART-Highly Active Antiretroviral Therapy, UOR-Unadjusted Odds Ratio, BMI-Body Mass Index, CD-Cluster of differentiation, NA- not applicable; Reference category: Male, Age ≤ 40 years, BMI < 25 kg/m², CD4+ T cell count ≥ 200 cells/μl, HIV duration < 42 months, HAART duration < 55 months, non-hypertensive, non-diabetic, non-obese, no alcohol intake.
The association between HAART and adverse lipid profile has been largely described for regimens that include PIs [23, 24], but this is contrary to our findings. This may be due to the small number of patients treated with PIs in our study. In this study, high TC and LDL-c were associated with HAART use. High TC was also associated with age >40 years, but no association could be found after adjusting for confounding factors. The association of high TC with age is well known as its risk increases with increased age [13, 28].

There is lack of data on HIV viral load to clearly define disease stages in the two groups. However, the CD4+ T cell counts gave a snapshot of disease progression in the untreated group and disease suppression in the treated group. Comprehensive cardiovascular risk stratifications were not assessed in this study. However, the increased risk of atherothrombotic cardiovascular disease associated with the described lipid derangement is well known [8, 29] and the long term use of HAART may have an impact on cardiovascular health. Our study, by nature is cross-sectional and inference about causal relationship is not possible. Cohort studies could monitor lipid profile alterations during HAART, and their potential impact on cardiovascular health of people living with HIV. Subsequent studies could address the issue of the small number of male participants, small number of patients in the HAART untreated group, and the lack of HIV-negative controls that our study could not handle.

### Conclusion

This study indicates that HIV-infected patients receiving WHO-recommended HAART treatment have a high prevalence of lipid profile derangements when compared to the HAART non-treated HIV-infected patients. Uses of HAART regimens are significantly associated with atherogenic lipid profiles. Lipid profile and other cardiovascular risk factors should be monitored in patients on ART so that any negative effects of HAART can be optimally managed. We recommend the implementation of well controlled cohort studies for the evaluation of long-term effects of HAART treatment on lipid profiles.

### Abbreviations

BMI: Body Mass Index; CI: Confidence Interval; SD: Standard Deviation; TC: Total Cholesterol; TG: Triglycerides; HDL-c: High Density Lipoproteins cholesterol; LDL-c: Low Density Lipoproteins cholesterol; STATA: Statistics/Data Analysis; HAART: Highly Active Antiretroviral Therapy; ART: Antiretroviral Therapy; PLWHA: People Living with HIV/AIDS; 3TC: Lamivudine; AZT: Zidovudine; TDF: Tenofovir; NVP: Nevirapine; EFV: Efavirenz; LPV/r: Lopinavir;
Pt: Protease Inhibitor; NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor; NRTI: Nucleoside Reverse Transcriptase Inhibitor; CD4+: Cluster of Differentiation.

Competing interests
The authors declare that they have no competing of interests.

Authors’ contribution
NDS participated in the conception, oversaw data collection and supervised the work, participated in data analysis, drafted the manuscript and substantially revised the manuscript for academic content; WEP, ANJC and NDS participated in design, data interpretation and drafting of the manuscript; TEA participated in the conception, designed the study, conducted the study, data analysis/interpretation and drafting of manuscript; KOD and ACW participated in the design, data interpretation and drafting of the manuscript; NMM oversaw data collection, supervised the work and substantially revised the manuscript for academic content. All authors read and approved the final copy.

Acknowledgments
We are grateful to the Directors and staff of the Limbe and Buea Regional Hospitals for their technical assistance in sample collection. Our gratitude goes to the HIV/AIDS patients for their voluntary participation and collaboration during this study.

Author details
1Department of Public Health and Hygiene, Faculty of Health Sciences, University of Buea, P.O Box 12, Buea, Cameroon. 2Department of Surgery, Obstetrics and Gynaecology, Faculty of Health Sciences, University of Buea, P.O Box 12, Buea, Cameroon. 3Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Buea, P.O Box 12, Buea, Cameroon.

Received: 7 May 2015 Accepted: 20 August 2015
Published online: 28 August 2015

References
1. Grinsztejn B, Luz PM, Pacheco AG, Santos DV, Velasque L, Moreira RI, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: Shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One. 2013;8(4):e59768.
2. Pacheco AG, Tuboi SH, Faulhaber JC, Harrison LH, Schechter M. Increase in the number of patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India. Clin Infect Dis. 2011;52:540–6.
3. Mondy K, Overton ET, Grabb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, mid-western US outpatient population. Clin Infect Dis. 2007;44:276–34.
4. Madhavan Padmapriyadarsini C, Ramesh Kumar S, Terrin N, Narendran G, Menon PA, Ramachandran G, et al. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India. J Infect Dis. 2011;15:52–60.
5. Mondy K, Overton ET, Grabb J, Tong S, Seyfried W, Powdery W, et al. Metabolic syndrome in HIV-infected patients from an urban, mid-western US outpatient population. Clin Infect Dis. 2007;44:276–34.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:51–8.
7. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:29–35.
8. Buchach K, Weidie PJ, Moore D, Were W, Mermin J, Downing R, et al. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr. 2008;47:304–11.
9. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
10. D’Ascenzo F, Cerrato E, Appleton D, Moretti C, Calzagno A, Abouzaki N, et al. Percutaneous coronary intervention and surgical revascularization in HIV Database (PHD) Study Investigators. Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes. use of registry data from 12 sites in Europe, South Africa and the United States. Thromb Res. 2014;134(3):558–64.
11. Bekolo CE, Nguea MB, Evane L, Bekuole PS, Kolo B. The lipid profile of HIV-infected patients receiving antiretroviral therapy in a rural Cameroonian population. BMC Public Health. 2014;14:236.
12. Tadeswo A, Addis Z, Ambachew H, Banejeje S. Prevalence of dyslipidemia among HIV-infected patients using first-line highly active antiretroviral therapy in Southern Ethiopia: a cross-sectional comparative group study. AIDS Res Ther. 2012;9(1):31.
13. Armstrong C, Liu E, Grinspoon S, Okuma J, Spiegelman D, Guerino C, et al. Dyslipidemia in an HIV-positive antiretroviral treatment-naïve population in Dar es Salaam Tanzania. J Acquir Immune Defic Syndr. 2011;57(2):145–5.
14. Sudano I, Speker LE, Noll G, Corti R, Weber R, Lüscher TF. Cardiovascular disease in HIV infection. Am Heart J. 2006;151:1147–55.
15. Yone PEW, Betyoumin AF, Kengeye AP, Folefack FJ, Ngogang J. First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon. AIDS Res Ther. 2011;8:33.
16. Kolyansundaram AP, Jacob SM, Hemalatha R, Sivakumar MR. Prevalence of Lipodystrophy and Dyslipidemia among Patients with HIV infection on generic ART in Rural South India. JAPIAC. 2011;000:1–6.
17. Manuthu EM, Joshi MD, Luke GN, Karan E. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. East Afr Med J. 2008;85:10–7.
18. Pujari SN, Dravid A, Naik E, Bhagat S, Tahs K, Nadler JP, et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005;39:199–202.
19. Eron Jr JJ, Murphy RL, Peterson D. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). AIDS. 2002;14:1601–10.
20. Gall M, Ridolfo AL, Adsoni F, Gervasoni C, Ravasio L, Corsico L, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21–31.
21. Gallant JE, Staszewski S, Pozniak AL, Delusio E, Sulurman JC, Miller MD, et al. Efficacy and safety of Tenofovir DF vs Stavudine in combination therapy in antiretroviral naive patients: a 3-year randomized trial. JAMA. 2002;292:199–201.
22. Kumar PN, Rodrigues-French A, Thompson MA, Tashima KT, Avett D, Wannamaker PG, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/Neilfavin, and lamivudine/stavudine/neifavir in lipids, metabolic parameters and efficacy in antiretroviral-naïve patients: effect of sex and ethnicity. J Infect Dis. 2006;195:98–102.
23. Domingos N, Cunha RN, Paniago AM, Martins DM, Elkhoury EB, Souza AS. Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis. 2009;13:30:6–10.
24. Nery MM, Martelli CMT, Turchi MD. Dyslipidemia in AIDS patients on highly active antiretroviral therapy. Braz J Infect Dis. 2011;15:151–5.
25. Young J, Weber R, Rickenbach M, Furrer H, Bernaschi E, Hirschel B, et al. Lipid profiles for antiretroviral-naïve patients starting PI- and NRTI-based therapy in the Swiss HIV cohort study. Antivir Ther. 2005;10:385–91.
26. Zannou DM, Denoueul L, Lacombe K, Arnoussou-Guenou D, Bash J, Akapo J, et al. Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin. Antivir Ther. 2009;14:371–80.
27. Almeida SE, Borges M, Fiegenbaum M, Nunes CC, Rossetti ML. Metabolic changes associated with antiretroviral therapy in HIV-positive patients. Rev Saude Publica. 2009;43:283–90.
28. Bekka P, Jaakko T, Bekka P, Sex, Age, Cardiovascular Risk Factors, and Coronary Heart Disease. J Am Heart Assoc. 1999;99:165–72.
29. Cahn P, Leite O, Rosales A, Cabello R, Alvarez CA, Seas C, et al. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART. J Infect Dis. 2010;191:1556–66.